

---

# MedImmune Patents

Matching "MedImmune" by Owner.

**IPMonitor**  
Patents

---

# Contents

Alerts	3
"MedImmune"	3
Terms and Conditions	11
General	11
Disclaimer of warranty and limitation of liability	11
Copyright	11
Arbitration	11

# Alerts

## "MedImmune"

216 results matching "MedImmune" by Owner.

Number	Title	Owner
<a href="#">2002306651</a>	Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists	Medimmune, Inc.
<a href="#">2002305471</a>	Chemoprotection using amifostine and related compounds	Medimmune Oncology, Inc.
<a href="#">2002322478</a>	METHODS OF ADMINISTERING/DOSING CD2 ANTAGONISTS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISORDERS OR INFLAMMATORY DISORDERS	MEDIMMUNE, INC.
<a href="#">2002327171</a>	CRYSTALS AND STRUCTURE OF SYNAGIS FAB	MEDIMMUNE, INC.
<a href="#">2001297896</a>	MUTANT PROTEINS, HIGH POTENCY INHIBITORY ANTIBODIES AND FIMCH CRYSTAL STRUCTURE	MEDIMMUNE, INC.
<a href="#">2002246900</a>	THERAPEUTIC COMPOUNDS STRUCTURALLY-LINKED TO BACTERIAL POLYPEPTIDES	MEDIMMUNE, INC. ; WASHINGTON UNIVERSITY
<a href="#">2002245321</a>	Methods for the administration of amifostine and related compounds	MedImmune Oncology, Inc.
<a href="#">2002248184</a>	Molecules with extended half-lives, compositions and uses thereof	Board of Regents, The University of Texas System ; Medimmune, Inc.
<a href="#">2002250236</a>	METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING CD2 ANTAGONISTS IN COMBINATION WITH OTHER PROPHYLACTIC OR THERAPEUTIC AGENTS	MEDIMMUNE, INC.
<a href="#">2003213682</a>	Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate	Medimmune, Inc.
<a href="#">2003217930</a>	The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents	MEDIMMUNE, INC.
<a href="#">2003219837</a>	Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences	ViroNovative BV ; MedImmune, LLC
<a href="#">2003219839</a>	Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus	Medimmune Vaccines, Inc. ; Vironovative BV
<a href="#">2003230908</a>	SPRAY FREEZE DRY OF COMPOSITIONS FOR INTRANASAL ADMINISTRATION	MEDIMMUNE VACCINES, INC.
<a href="#">2003231083</a>	Multi plasmid system for the production of influenza virus	MEDIMMUNE VACCINES, INC.
<a href="#">2003226065</a>	Recombinant anti-interleukin-9 antibodies	Ludwig Institute for Cancer Research, Ltd ; MedImmune, LLC
<a href="#">2003221888</a>	Preservation of bioactive materials by spray drying	MedImmune, LLC

Number	Title	Owner
<a href="#">2003234090</a>	SPRAY FREEZE DRY OF COMPOSITIONS FOR PULMONARY ADMINISTRATION	MEDIMMUNE VACCINES, INC.
<a href="#">2003243228</a>	EphA2 monoclonal antibodies and methods of use thereof	MedImmune, LLC
<a href="#">2003245515</a>	Stabilized liquid anti-RSV antibody formulations	Medimmune, Inc.
<a href="#">2003247337</a>	Preservation of bioactive materials by freeze dried foam	MedImmune Vaccines, Inc.
<a href="#">2003256823</a>	Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies	ViroNovative B.V. ; MedImmune, LLC
<a href="#">2003273299</a>	Methods of preventing or treating cell malignancies by administering CD2 antagonists	National Cancer Institute ; MedImmune, LLC
<a href="#">2003276402</a>	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations	MedImmune, LLC
<a href="#">2003288675</a>	Antibodies against PD-1 and uses therefor	Wyeth ; MedImmune Limited
<a href="#">2003295339</a>	Functional mutations in respiratory syncytial virus	MedImmune, LLC
<a href="#">2003297320</a>	High pressure spray-dry of bioactive materials	MedImmune Vaccines, Inc.
<a href="#">2004203350</a>	Stable amorphous amifostine compositions and methods for the preparation and use of same	MedImmune Oncology, Inc.
<a href="#">2001275458</a>	Chimeric human papillomavirus (HPV) L1 molecules and uses therefor	Medimmune, Inc.
<a href="#">2004207002</a>	Uses of integrin alphavbeta3 antagonists	Medimmune, Inc.
<a href="#">2004207003</a>	Anti-integrin alphanubeta3 antibody formulations and uses thereof	Medimmune, Inc.
<a href="#">2004263813</a>	Methods of producing influenza vaccine compositions	MedImmune Vaccines, Inc.
<a href="#">2004226369</a>	Compositions and methods involving respiratory syncytial virus subgroup B strain 9320	MedImmune Vaccines, Inc.
<a href="#">2004229501</a>	Recombinant IL-9 antibodies and uses thereof	MedImmune, LLC
<a href="#">2004229527</a>	Methods of preventing or treating respiratory conditions	MedImmune, LLC
<a href="#">2004229543</a>	EphA2 and non-neoplastic hyperproliferative cell disorders	Medimmune, Inc.
<a href="#">2004230539</a>	EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution	Medimmune, Inc.
<a href="#">2004235347</a>	Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus	ViroNovative BV ; MedImmune, LLC
<a href="#">2004273776</a>	Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus	ViroNovative B.V. ; MedImmune, LLC
<a href="#">2002219944</a>	Methods of administering/dosing antiRSV antibodies for prophylaxis and treatment	MedImmune, Inc
<a href="#">2004291026</a>	Use of EphA4 and modulator or EphA4 for diagnosis, treatment and prevention of cancer	MedImmune, Inc.
<a href="#">2004261603</a>	EphA2 T-cell epitope agonists and uses therefor	University of Pittsburgh-of the Commonwealth System of Higher Education ; Medimmune, Inc.
<a href="#">2006200619</a>	Recombinant RSV virus expression systems and vaccines	MedImmune Vaccines, Inc.
<a href="#">2004256976</a>	Human antibody molecules for IL-13	MedImmune Limited
<a href="#">2004286198</a>	Humanization of antibodies	MedImmune, LLC

Number	Title	Owner
<a href="#">2004280333</a>	Humanization of antibodies	MedImmune, Inc.
<a href="#">2004281834</a>	Listeria-based EphA2 vaccines	Cerus Corporation ; MedImmune, Inc.
<a href="#">2001261137</a>	Combination therapy of respiratory diseases using antibodies and antiinflammatory agents	Medimmune, Inc. ; Virion Systems Inc.
<a href="#">2004293034</a>	EphA2 agonistic monoclonal antibodies and methods of use thereof	MedImmune, LLC ; Purdue Research Foundation
<a href="#">2001255772</a>	Immunogenic pneumococcal protein and vaccine compositions thereof	Medimmune, Inc
<a href="#">2001249326</a>	Recombinant parainfluenza virus expression systems and vaccines	MedImmune Vaccines, Inc.
<a href="#">2002236522</a>	Recombinant RSV virus expression systems and vaccines	MedImmune Vaccines, Inc.
<a href="#">2006203015</a>	Ultra high affinity neutralizing antibodies	Applied Molecular Evolution, Inc. ; MedImmune, LLC
<a href="#">2004308328</a>	Multi plasmid system for the production of influenza virus	MedImmune, LLC
<a href="#">2001259379</a>	Combination therapy of respiratory diseases using antibodies	Medimmune, Inc.
<a href="#">2006203134</a>	Methods of administering/dosing antiRSV antibodies for prophylaxis and treatment	MedImmune, LLC
<a href="#">2006203171</a>	Combination therapy of respiratory diseases using antibodies and antiinflammatory agents	Medimmune, Inc. ; Virion Systems, Inc.
<a href="#">2006225333</a>	Combination therapy of respiratory diseases using antibodies	Medimmune, Inc.
<a href="#">2005249360</a>	Anti-IL-9 antibody formulations and uses thereof	MedImmune, LLC
<a href="#">2005254062</a>	High pressure spray-dry of bioactive materials	MedImmune, LLC
<a href="#">2005248375</a>	Influenza hemagglutinin and neuraminidase variants	MedImmune, LLC
<a href="#">2005248377</a>	Influenza hemagglutinin and neuraminidase variants	The Government of the United States of America ; MedImmune, LLC
<a href="#">2005259992</a>	Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis	MedImmune, Inc.
<a href="#">2001240020</a>	High potency recombinant antibodies and method for producing them	Medimmune, Inc. ; Applied Molecular Evolution, Inc.
<a href="#">2005277567</a>	Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity	MedImmune, Inc.
<a href="#">2005277641</a>	Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity	MedImmune, Inc.
<a href="#">2005286770</a>	Antibodies against and methods for producing vaccines for respiratory syncytial virus	MedImmune, Inc.
<a href="#">2007201825</a>	Recombinant parainfluenza virus expression systems and vaccines	MedImmune Vaccines, Inc.
<a href="#">2005294528</a>	Refrigerator-temperature stable influenza vaccine compositions	MedImmune, LLC
<a href="#">2007202040</a>	High potency recombinant antibodies and method for producing them	Applied Molecular Evolution, Inc. ; MedImmune, LLC
<a href="#">2005302453</a>	Methods of preventing and treating RSV infections and related conditions	Medimmune, Inc.
<a href="#">2005295158</a>	High cell density process for growth of Listeria	MedImmune, Inc.
<a href="#">2005302274</a>	Ultra high throughput capture lift screening methods	MedImmune, Inc.

Number	Title	Owner
<a href="#">2005333602</a>	High affinity antibodies against HMGB1 and methods of use thereof	MedImmune, LLC
<a href="#">2005299353</a>	Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections	MedImmune, Inc.
<a href="#">2005299354</a>	Modulators of EphA2 and ephrina1 for the treatment of fibrosis-related disease	MedImmune, Inc.
<a href="#">2005299355</a>	Modulation of antibody specificity by tailoring the affinity to cognate antigens	MedImmune, Inc.
<a href="#">2006207338</a>	Specific binding members for NGF	Elan Pharma International Limited ; MedImmune Limited
<a href="#">2005314138</a>	Methods of producing influenza vaccine compositions	MedImmune, LLC
<a href="#">2006204396</a>	Method of mutagenesis	MedImmune Limited
<a href="#">2005322353</a>	Non-tumorigenic MDCK cell line for propagating viruses	MedImmune, LLC
<a href="#">2006218816</a>	Influenza virus harvester	Medimmune Vaccines, Inc.
<a href="#">2006223002</a>	Macromolecules comprising a thioether cross-link	MedImmune, Inc.
<a href="#">2007219282</a>	Chemoprotection using amifostine and related compounds	Medimmune Oncology, Inc.
<a href="#">2006223138</a>	Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus	MedImmune, LLC
<a href="#">2006234788</a>	A host cell comprising a vector for production of proteins requiring gammacarboxylation	MedImmune, Limited
<a href="#">2006227377</a>	Framework-shuffling of antibodies	Medimmune, Inc.
<a href="#">2006234847</a>	Antibodies against mammalian metapneumovirus	MedImmune, Inc.
<a href="#">2007231918</a>	Preservation of bioactive materials by freeze dried foam	MedImmune, LLC
<a href="#">2006239851</a>	Modulation of antibody effector function by hinge domain engineering	MedImmune, LLC
<a href="#">2006265936</a>	An integrated approach for generating multidomain protein therapeutics	Medimmune, Inc.
<a href="#">2006262380</a>	Methods and compositions for expressing a heterologous protease	MedImmune Vaccines, Inc.
<a href="#">2006262381</a>	Methods and compositions for expressing negative-sense viral RNA in canine cells	MedImmune Vaccines, Inc.
<a href="#">2008200401</a>	Recombinant RSV virus expression systems and vaccines	MedImmune Vaccines, Inc.
<a href="#">2008201162</a>	Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphavbeta3 antagonists in combination with other prophylactic or therapeutic agents	Medimmune, Inc.
<a href="#">2008201113</a>	Recombinant RSV virus expression systems and vaccines	MedImmune Vaccines, Inc.
<a href="#">2006296399</a>	Interleukin-13 antibody composition	Medimmune Limited
<a href="#">2008201419</a>	Molecules with extended half-lives, compositions and uses thereof	Board of Regents, The University of Texas System ; MedImmune, LLC
<a href="#">2008201412</a>	Combination therapy of respiratory diseases using antibodies and antiinflammatory agents	MedImmune, Inc ; Virion Systems, Inc.
<a href="#">2006287416</a>	Toxin conjugated Eph receptor antibodies	Medimmune, Inc. ; Seattle Genetics, Inc.
<a href="#">2008201720</a>	High pressure spray-dry of bioactive materials	MedImmune, LLC

Number	Title	Owner
<a href="#">2006297304</a>	Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells	MedImmune, LLC
<a href="#">2006304387</a>	Cell display of antibody libraries	Medimmune, Inc.
<a href="#">2008202076</a>	Methods of administering/dosing antiRSV antibodies for prophylaxis and treatment	MedImmune, LLC
<a href="#">2008202252</a>	Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus	MedImmune, LLC
<a href="#">2006304898</a>	Multi-plasmid system for the production of influenza virus	MedImmune, LLC
<a href="#">2006330807</a>	Antagonists of HMBG1 and/or rage and methods of use thereof	MedImmune
<a href="#">2006327175</a>	Epha2 bite molecules and uses thereof	Micromet AG ; MedImmune, Inc.
<a href="#">2008202925</a>	Stabilized liquid anti-RSV antibody formulations	MedImmune, LLC
<a href="#">2006331775</a>	Affinity optimized EphA2 agonistic antibodies and methods of use thereof	MedImmune, Inc.
<a href="#">2007212147</a>	Protein formulations	MedImmune, Inc.
<a href="#">2007217751</a>	Antibodies against human IL-22 and uses therefor	MedImmune Limited; Wyeth
<a href="#">2007223903</a>	Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease	MedImmune, Inc.
<a href="#">2007231128</a>	Binding member for GM-CSF receptor	MedImmune Limited ; Zenyth Operations Pty. Ltd.
<a href="#">2008230033</a>	Methods of producing influenza vaccine compositions	MedImmune, LLC
<a href="#">2007240448</a>	Methods and compositions for expressing negative-sense viral RNA in canine cells	Medimmune LLC.
<a href="#">2009200127</a>	Preservation of bioactive materials by freeze dried foam	MedImmune, LLC
<a href="#">2009200301</a>	Preservation of bioactive materials by spray drying	MedImmune, LLC
<a href="#">2007348941</a>	Antibodies directed to alphaVbeta6 and uses thereof	MedImmune Limited
<a href="#">2007286161</a>	Influenza hemagglutinin and neuraminidase variants	MedImmune, LLC ; The Government of The United States of America National Institutes of Health
<a href="#">2009200666</a>	The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents	MedImmune, LLC
<a href="#">2007294575</a>	Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease	MedImmune, LLC
<a href="#">2007347716</a>	MDCK cell lines supporting viral growth to high titers and bioreactor process using the same	Medimmune Vaccines, Inc.
<a href="#">2007300221</a>	Stabilized antibody formulations and uses thereof	Medimmune, LLC
<a href="#">2007313300</a>	Molecules with reduced half-lives, compositions and uses thereof	Medimmune, LLC.
<a href="#">2007311608</a>	Protein variants	MedImmune Limited
<a href="#">2007327090</a>	Binding members for interleukin-6	AstraZeneca AB ; MedImmune Limited
<a href="#">2007327096</a>	Antibodies specific for the complex of Interleukin-6 and the Interleukin-6 receptor	AstraZeneca AB ; MedImmune Limited
<a href="#">2009201985</a>	Recombinant anti-interleukin-9 antibodies	Ludwig Institute for Cancer Research, Ltd ; MedImmune, LLC

Number	Title	Owner
<a href="#">2007327995</a>	Interferon alpha-induced pharmacodynamic markers	MedImmune, LLC
<a href="#">2007327993</a>	Methods of treating systemic lupus erythematosus	MedImmune, LLC.
<a href="#">2009202542</a>	EphA2 monoclonal antibodies and methods of use thereof	MedImmune, LLC
<a href="#">2008216008</a>	Binding members for IgE molecules	AstraZeneca AB ; MedImmune Limited
<a href="#">2008217581</a>	Monoclonal anti-CXCL13 antibodies	AstraZeneca AB ; MedImmune Limited
<a href="#">2008215926</a>	Binding members for IgE molecules	AstraZeneca AB; MedImmune Limited
<a href="#">2008216418</a>	Antibody library display by yeast cell plasma membrane	MedImmune, Inc.
<a href="#">2008230177</a>	Fusion protein capable of degrading amyloid beta peptide	MedImmune Limited
<a href="#">2009225296</a>	Multi-plasmid system for the production of influenza virus	MedImmune, LLC
<a href="#">2008232903</a>	Antibodies with decreased deamidation profiles	MedImmune, Inc.
<a href="#">2008232902</a>	Antibody formulation	MedImmune, Inc.
<a href="#">2008247382</a>	Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease	MedImmune, LLC
<a href="#">2009238341</a>	Methods of preventing or treating respiratory conditions	MedImmune, LLC
<a href="#">2009239780</a>	Epha2 agonistic monoclonal antibodies and methods of use thereof	Purdue Research Foundation ; MedImmune, LLC
<a href="#">2008247398</a>	Interferon alpha-induced pharmacodynamic markers	MedImmune, Inc.
<a href="#">2008255027</a>	Methods of reducing eosinophil levels	MedImmune, LLC ; Biowa, Inc.
<a href="#">2008268362</a>	Methods of treating RSV infections and related conditions	MedImmune, LLC
<a href="#">2008254704</a>	IL-33 in inflammatory disease	MedImmune, LLC
<a href="#">2008254705</a>	IL-9 in fibrotic and inflammatory disease	MedImmune, LLC
<a href="#">2008265760</a>	Influenza B viruses having alterations in the hemagglutinin polypeptide	MedImmune, LLC
<a href="#">2008257801</a>	RSV-specific binding molecules and means for producing them	MedImmune Ltd
<a href="#">2008247395</a>	Auto-antibody markers of autoimmune disease	MedImmune, LLC
<a href="#">2008265928</a>	Synergistic treatment of cells that express EphA2 and ErbB2	MedImmune, LLC ; Vanderbilt University
<a href="#">2008275828</a>	Method for production of recombinant human thrombin `644	MedImmune Limited
<a href="#">2008282218</a>	Multispecific epitope binding proteins and uses thereof	MedImmune, LLC
<a href="#">2010200956</a>	Methods of preventing or treating T cell malignancies by administering CD2 antagonists	National Cancer Institute ; MedImmune, LLC.
<a href="#">2010201090</a>	Ultra high affinity neutralizing antibodies	MedImmune, LLC
<a href="#">2008319298</a>	Protein scaffolds	MedImmune, LLC
<a href="#">2008324800</a>	Methods of treating scleroderma	MedImmune, LLC.
<a href="#">2010202006</a>	Methods of administering/dosing antiRSV antibodies for prophylaxis and treatment	MedImmune, LLC
<a href="#">2008339576</a>	Binding members for interleukin-4 receptor alpha (IL-4Ralpha) - 173	MedImmune Limited
<a href="#">2009205995</a>	Cysteine engineered antibodies for sitespecific conjugation	MedImmune, LLC



Number	Title	Owner
<a href="#">2009209251</a>	Stabilized Angiopoietin-2 antibodies and uses thereof	MedImmune Limited
<a href="#">2009212273</a>	Anti-IFNAR1 antibodies with reduced Fc ligand affinity	MedImmune, LLC
<a href="#">2010212375</a>	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations	MedImmune, LLC
<a href="#">2009212216</a>	Disease markers and uses thereof	MedImmune, LLC ; Brigham and Women's Hospital, Inc.
<a href="#">2010219289</a>	High potency recombinant antibodies and method for producing them	MedImmune, LLC ; Applied Molecular Evolution, Inc.
<a href="#">2010227001</a>	Humanization of antibodies	MedImmune, LLC
<a href="#">2010235966</a>	Antibodies Against PD-1 and Uses Therefor	Wyeth ; MedImmune Limited
<a href="#">2009248809</a>	Interleukin-21 receptor binding proteins	MedImmune Limited ; Wyeth LLC
<a href="#">2011200308</a>	Human antibody molecules for IL-13	MedImmune Limited
<a href="#">2009268576</a>	Influenza hemagglutinin and neuraminidase variants	MedImmune, LLC
<a href="#">2009294416</a>	Antibodies against sonic hedgehog homolog and uses thereof	MedImmune LLC
<a href="#">2009294415</a>	Antibodies directed to DLL4 and uses thereof	MedImmune LLC
<a href="#">2011201022</a>	Influenza hemagglutinin and neuraminidase variants	MedImmune, LLC
<a href="#">2011201326</a>	Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer	MedImmune Limited
<a href="#">2009296628</a>	Methods for purification of viruses	MedImmune, LLC
<a href="#">2009296701</a>	Methods for cultivating cells, propagating and purifying viruses	MedImmune, LLC
<a href="#">2009294414</a>	Antibodies directed to CD105 and uses thereof	MedImmune LLC
<a href="#">2009314099</a>	Antibody formulation	MedImmune, LLC
<a href="#">2009312562</a>	Binding members against IL-1R1	MedImmune Limited
<a href="#">2009329348</a>	Binding members for interleukin-4 receptor alpha (IL-4Ra) - 836	MedImmune Limited
<a href="#">2011203314</a>	Refrigerator-temperature stable influenza vaccine compositions	MedImmune, LLC
<a href="#">2010208125</a>	Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases	MedImmune, LLC
<a href="#">2010213966</a>	Influenza hemagglutinin and neuraminidase variants	The Government of The United States of America National Institutes of Health ; MedImmune, LLC
<a href="#">2011221380</a>	Modulation of antibody effector function by hinge domain engineering	MedImmune, LLC
<a href="#">2010221099</a>	Humanized anti-CD19 antibody formulations	MedImmune, LLC
<a href="#">2011226771</a>	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations	MedImmune, LLC
<a href="#">2011244909</a>	Recombinant parainfluenza virus expression systems and vaccines	MedImmune, LLC
<a href="#">2011253620</a>	Non-tumorigenic MDCK cell line for propagating viruses	MedImmune, LLC
<a href="#">2011253690</a>	Molecules with extended half-lives, compositions and uses thereof	MedImmune, LLC ; Board of Regents, The University of Texas System
<a href="#">2010266078</a>	Swine influenza hemagglutinin variants	MedImmune, LLC
<a href="#">2010270979</a>	Engineered Fc regions for site-specific conjugation	MedImmune, LLC
<a href="#">2010262974</a>	Protease variants	MedImmune, LLC

Number	Title	Owner
<a href="#">2012200987</a>	Methods of preventing and treating RSV infections and related conditions	MedImmune, LLC
<a href="#">2012201535</a>	Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus	MedImmune, LLC
<a href="#">2012201931</a>	Multi-plasmid system for the production of influenza virus	MedImmune, LLC
<a href="#">2010289383</a>	Type 1 interferon diagnostic	MedImmune, LLC
<a href="#">2009353693</a>	RSV-specific binding molecule	MedImmune Ltd
<a href="#">2012201973</a>	Methods of producing influenza vaccine compositions	MedImmune, LLC
<a href="#">2012202120</a>	Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer	MedImmune Limited
<a href="#">2010307020</a>	Quantification of IR-A and IR-B for tumor classification	MedImmune, LLC
<a href="#">2010324757</a>	Targeted binding agents against B7-H1	MedImmune Limited
<a href="#">2010326174</a>	Improved methods and compositions for detecting and treating CEA-expressing cancers	MedImmune, LLC
<a href="#">2012204078</a>	Binding members for IgE molecules	AstraZeneca AB; MedImmune Limited
<a href="#">2012216506</a>	Antibodies against mammalian metapneumovirus	MedImmune, LLC
<a href="#">2012207007</a>	Influenza hemagglutinin and neuraminidase variants	MedImmune, LLC
<a href="#">2012207043</a>	Antibody formulations having optimized aggregation and fragment profiles	MedImmune, LLC
<a href="#">2012211451</a>	High potency recombinant antibodies and method for producing them	MedImmune, LLC; Applied Molecular Evolution, Inc.
<a href="#">2012213962</a>	Ultra high affinity neutralizing antibodies	MedImmune, LLC
<a href="#">2012213964</a>	Methods of administering/dosing antiRSV antibodies for prophylaxis and treatment	MedImmune, LLC
<a href="#">2011218294</a>	HSA-related compositions and methods of use	MedImmune, LLC
<a href="#">2011240620</a>	Fibronectin type III domain-based multimeric scaffolds	MedImmune, LLC
<a href="#">2011240624</a>	TRAIL R2-specific multimeric scaffolds	MedImmune, LLC
<a href="#">2012238233</a>	Binding members for IgE molecules	AstraZeneca AB; MedImmune Limited
<a href="#">2011239402</a>	Compositions and methods for treating COPD exacerbation	MedImmune Limited; McMaster University
<a href="#">2012241127</a>	Macromolecules comprising a thioether cross-link	MedImmune, LLC

---

# Terms and Conditions

## General

The information provided in this report is not in the nature of legal or other professional advice.

The information provided in this report is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals regarding any information in this report.

Patents, patent applications, trademarks and trademark applications shown as lapsed or ceased may be restored at a later date.

## Disclaimer of warranty and limitation of liability

Neither IPMonitor, its affiliates nor any of their respective employees, agents, third party content providers or licensors warrant that the information contained in this report is error free; nor do they make any warranty as to the accuracy, reliability or content of any information in this report.

This report is provided on an "as is" basis; to the maximum extent permitted by law, IPMonitor disclaims all representations and warranties, express or implied, with respect to any information contained in this report. In addition, IPMonitor does not represent or warrant that the information contained in this report is accurate, complete or current.

This disclaimer of liability applies to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action.

## Copyright

The content of this report may be protected by copyright laws and treaties around the world and all rights relating to the same are reserved. Any paper or digital copies of this report are not to be modified or any illustrations or any graphics used separately from any accompanying text.

## Arbitration

Any dispute or difference whatsoever arising out of or in connection with this report shall be submitted to arbitration in accordance with, and subject to, The Institute of Arbitrators & Mediators Australia Rules for the Conduct of Commercial Arbitrations.

IPMonitor reserves the right to update the Terms and Conditions at any time without notice. Please see the full Terms and Conditions at [www.IPMonitor.com.au/trademarks/info/terms](http://www.IPMonitor.com.au/trademarks/info/terms)